Table 1.

Clinicopathological information in patients with esophageal squamous cell carcinoma.

Variable	Group	Group A	Group P	χ2	P-value
Sex	Male	54	53	0.03a	0.86
	Female	25	26
Age, years	≤60	23	20	0.29a	0.59
	>60	56	59
History of smoking	Yes	40	38	0.10a	0.75
	No	39	41
History of alcohol use	Yes	50	49	0.03a	0.87
	No	29	30
History of hypertension	Yes	55	58	0.28a	0.60
	No	24	21
History of CHD	Yes	16	6	5.28a	0.02
	No	63	73
History of diabetes	Yes	11	12	0.05a	0.82
	No	68	67
Tumor location	Upper 1/3 thoracic segment	7	8	0.08a	0.96
	Middle 1/3	53	52
	Lower 1/3	19	19
Tumor size, cm	<5/	43	51	1.68a	0.20
	≥5	36	28
Degree of differentiation	Undetermined and well differentiated	71	73	0.31a	0.58
	Moderate and poorly differentiated	8	6
T stage	Tis	1	3	6.34a	0.18
	T1	15	14
	T2	18	13
	T3	39	48
	T4	6	1
N stage	N0	52	57	3.58a	0.31
	N1	19	16
	N2	5	6
	N3	3	0
TNM stage	0	2	3	0.70a	0.87
	I	17	17
	II	37	40
	III	23	19
Lymph node metastasis	Yes	27	22	0.74a	0.39
	No	52	57
LNR	0	52	57	4.37a	0.11
	>0 to ≤0.1	11	15
	>0.1	16	7
Margin-positive	Yes	5	3	0.53a	0.47
	No	74	76
Vascular tumor invasion	Yes	6	2	2.11a	0.15
	No	73	77
Neural tumor invasion	Yes	9	6	0.66a	0.42
	No	70	73
Neoadjuvant radiochemotherapy	Yes	5	2	1.35a	0.25
	No	74	77
Postoperative complication	Yes	22	21	0.03a	0.86
	No	57	58
Postoperative neoadjuvant therapy	No adjuvant therapy	42	40	11.98a	0.01
	Radiotherapy alone	2	12
	Chemotherapy alone	22	23
	Radiochemotherapy	13	4

^aExpected count of 0 cells (0.0%) <5; minimum expected count 25.50.

CHD, coronary heart disease; LNR, lymph node ratio.